Ccl18

Manufactured by Thermo Fisher Scientific

Sourced in United States

The CCL18 is a laboratory equipment product designed for use in scientific research and testing. It serves as a core component in various analytical and experimental procedures. The CCL18 is a technical device with specific functionalities, and its detailed description is provided without any interpretation or extrapolation on intended use.

Automatically generated - may contain errors

Lab products found in correlation

Rpmi 1640 medium, by Thermo Fisher Scientific (1 mentions) Hyclone, by GE Healthcare (1 mentions) Anti β1 integrin, by Merck Group (1 mentions) Il 10, by Thermo Fisher Scientific (1 mentions) Interleukin 6 (il 6), by Thermo Fisher Scientific (1 mentions) Hepatocyte growth factor (hgf), by Thermo Fisher Scientific (1 mentions) Actinomycin d, by Merck Group (1 mentions) Generation 3 array scanner, by Cytiva (1 mentions) Elisa development kit, by Thermo Fisher Scientific (1 mentions) Rpmi 1640, by Thermo Fisher Scientific (1 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

Recombinant human CCL18 (rCCL18) (3 citations) Human recombinant CCL18 (2 citations)

5 protocols using ccl18

Treating Cholangiocarcinoma Cells with CCL18

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human cholangiocarcinoma cell lines HCCC‐9810 and CCLP‐1 were purchased from Shanghai BioLeaf Biotech Co., Ltd., and human monocyte THP‐1 cells were purchased from the National Collection of Authenticated Cell Cultures. The cells were cultured in RPMI 1640 (Gibco™, Thermo Fisher Scientific) medium supplemented with 10% fetal bovine serum (Gibco™, Thermo Fisher Scientific) and 1% penicillin–streptomycin (Gibco™, Thermo Fisher Scientific). For CCL18 treatment experiments, ICC cells were treated with indicated conditioned medium (CM) with or without 20 ng/mL CCL18 (Peprotech) before conducting further functional experiments. The application concentration of CCL18 was determined based on previous research.
²⁴ (link),
²⁵ (link),
²⁶ (link),
²⁷ (link)

Zhou M., Yu H., Bai M., Lu S., Wang C., Ke S., Huang J., Li Z., Xu Y., Yin B., Li X., Feng Z., Fu Y., Jiang H, & Ma Y. (2024). IRG1 restrains M2 macrophage polarization and suppresses intrahepatic cholangiocarcinoma progression via the CCL18/STAT3 pathway. Cancer Science, 115(3), 777-790.

+ Open protocol

+ Expand

Chemokine Receptor Inhibition in Bladder Cancer

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The 5637 human BC cell line was purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Shanghai Institute of Cell Biology (Shanghai, China) and was maintained in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Media were supplemented with 10% heat-inactivated fetal bovine serum (FBS; HyClone; GE Healthcare Life Sciences, Logan, UT, USA), 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a humidified incubator containing 5% CO₂. The small molecule CCR8 inhibitor R243 (cat. no. AOB2014) was purchased from AOBIOUS, Inc. (Gloucester, MA, USA). For chemokine treatment, 5637 cells pretreated with or without R243 (5 µM) for 6 h at 37°C/5% carbon dioxide (16 (link)), were exposed to 50 or 100 ng/ml CCL18 (PeproTech, Inc., Rockville, MD, USA) for 36 h.

Liu X., Xu X., Deng W., Huang M., Wu Y., Zhou Z., Zhu K., Wang Y., Cheng X., Zhou X., Chen L., Li Y., Wang G, & Fu B. (2018). CCL18 enhances migration, invasion and EMT by binding CCR8 in bladder cancer cells. Molecular Medicine Reports, 19(3), 1678-1686.

+ Open protocol

+ Expand

HPMC-Conditioned Media Generation

Check if the same lab product or an alternative is used in the 5 most similar protocols

To generate HPMCs-conditioned media, HPMCs were cultured in twelve-well plates in complete medium until they reached 80% density. Cultured media was removed, cells were washed twice, starved for 4 h in growth hormone and FBS-free medium and treated overnight in growth hormone free medium containing no FBS, FBS 10%, benign fluid 10%, malignant ascites 0.001–10%, malignant ascites 10% heat inactivated at 100 °C for 10 min, TNF-alpha (20 ng/ml) (New England Biolabs, Whitby, ON), IL-10 (1 ng/ml), IL-6 (2 ng/ml), HGF (1 ng/ml), CCL18 (20 ng/ml), CCL7, CCL8, CCL16, CCL20, CXCL1, IL1-R4 (all at 10 ng/ml) (Peprotech, Rocky Hill NJ), Leptin (0.5 ng/ml) (RnD Systems, Minneapolis MN), Actinomycin D (8 nM), NF-kB Inhibitor BAY117082 (Sigma), anti-β1 Integrin or anti-αvβ5 (5 μg/ml) (EMD Millipore, Burlington, MA). When inhibitors or Actinomycin D were used, cells were preincubated 1 h prior the treatment with the inhibitor alone and then treated overnight as described. Cells were washed three times and fresh medium without FBS nor growth factors were added in each well. HPMCs were cultured for 24–96 h and medium conditioned by stimulated HPMCs were subjected to CA125 quantification. Results were normalized to the total protein concentration in the cell lysate and expressed as kilounits of MUC16 per gram of total proteins.

Matte I., Garde-Granger P., Bessette P, & Piché A. (2019). Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway. BMC Cancer, 19, 406.

+ Open protocol

+ Expand

MDA-MB-231 miRNA Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The miRNA expression changes between the MDA-MB-231 parental cells co-cultured with M2 macrophages or treated by CCL18 (PeproTech, USA) and the untreated ones were analyzed using Generation III array scanner (Amersham Pharmacia Biotech, USA) under the manufacturer's recommendations.

Lin X., Chen L., Yao Y., Zhao R., Cui X., Chen J., Hou K., Zhang M., Su F., Chen J, & Song E. (2015). CCL18-mediated down-regulation of miR98 and miR27b promotes breast cancer metastasis. Oncotarget, 6(24), 20485-20499.

+ Open protocol

+ Expand

Cytokine Release Measurement Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the release experiment
of both VEGF and IL-4, the fresh buffer solution (1 mL) was added
after each record and then supernatants were kept at −80 °C
prior to analysis. The levels of cytokines were measured with ELISA
Development Kits (VEGF, IL-4, IL1-RA, IL-6, IL-8, TNF-α, CCL18,
PeproTech). Standard curves were constructed with the included standard
protein in phosphate buffer. Samples were analyzed according to the
manufacturer’s protocol. The absorbance was measured at 450
nm with SpectraMax Paradigm.

Knopf-Marques H., Barthes J., Wolfova L., Vidal B., Koenig G., Bacharouche J., Francius G., Sadam H., Liivas U., Lavalle P, & Vrana N.E. (2017). Auxiliary Biomembranes as a Directional Delivery System To Control Biological Events in Cell-Laden Tissue-Engineering Scaffolds. ACS Omega, 2(3), 918-929.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!